Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L5 pseudogene 26 (RPL5P26) is a processed pseudogene—a non-functional genomic sequence resembling the ribosomal protein L5 (RPL5) gene. Unlike its parent gene, RPL5P26 does not encode a functional protein and typically has no biological activity. There are many processed pseudogenes of ribosomal proteins scattered throughout the genome; they are typically regarded as genomic fossils with no direct involvement in cellular function or disease. RPL5P26 is not a therapeutic target, receptor, enzyme, or transporter[5]. Context and clarification: - Pseudogenes like RPL5P26 are genomically similar to protein-coding genes but usually lack protein-coding potential due to disabling mutations or the absence of regulatory elements required for expression[5]. - The functional gene RPL5 (Ribosomal protein L5) is essential for ribosome assembly and has disease relevance, but pseudogenes such as RPL5P26 do not share these properties[1][4]. - Based on gene databases, RPL5P26 lacks evidence for functional protein expression, disease involvement, or druggability, thus should not be listed as a therapeutic target[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L5 pseudogene 26 (RPL5P26).